Oligonucleotide-mediated AASS silencing as a potential therapeutic strategy for ALDH7A1 deficiency and glutaric aciduria type I

α-Aminoadipic semialdehyde synthase (AASS) catalyzes the first two steps of lysine catabolism. Inherited metabolic disorders affecting enzymes downstream of AASS, including α-aminoadipic semialdehyde dehydrogenase (ALDH7A1) deficiency, which causes pyridoxine-dependent epilepsy, and glutaric aciduria type I, cause accumulation of potentially neurotoxic lysine-derived metabolites. Current therapies incompletely prevent metabolite accumulation and neurological sequelae. We evaluated whether hepatic AASS silencing could reduce conversion of lysine into downstream metabolites. Antisense oligonucleotides and small interfering RNAs targeting AASS reduced disease-associated metabolites in patient-derived cells from individuals with ALDH7A1 deficiency and glutaric aciduria type I. Hepatocyte-selective delivery, enabled by N -acetylgalactosamine conjugation, achieved >90% liver-specific Aass knockdown in wild-type and Aldh7a1 knockout mice, with sustained protein suppression and reduced accumulation of downstream lysine-derived metabolites. These findings support further evaluation of oligonucleotide-mediated AASS silencing, including liver-directed delivery, as a substrate reduction strategy for ALDH7A1 deficiency and glutaric aciduria type I.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2026-11-18
DOI
https://doi.org/10.1126/scitranslmed.aei9706
Primary Topic
Metabolism and Genetic Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Oligonucleotide-mediated AASS silencing as a potential therapeutic strategy for ALDH7A1 deficiency and glutaric aciduria type I

Charalambos Demetriou, Sam Rowley, Julien Baruteau, Joanna Toporowska et al.
4 links
Science Translational Medicine
Metabolism and Genetic Disorders
article

Oligonucleotide-mediated AASS silencing as a potential therapeutic strategy for ALDH7A1 deficiency and glutaric aciduria type I

Charalambos Demetriou, Sam Rowley, Julien Baruteau, Joanna Toporowska, Youssef Khalil, Sreekanth Vootukuri Reddy, Peter Theodore Clayton, Nicholas D. E. Greene, Izabella Agostinho Pena, Katarzyna Dyjach, Philippa B. Mills, Sídney M. Gospe, Haiyan Zhou, Paul Gissen, Kyle O’Sullivan, Barbara Plecko, Alex Mackensie
article en

Abstract

α-Aminoadipic semialdehyde synthase (AASS) catalyzes the first two steps of lysine catabolism. Inherited metabolic disorders affecting enzymes downstream of AASS, including α-aminoadipic semialdehyde dehydrogenase (ALDH7A1) deficiency, which causes pyridoxine-dependent epilepsy, and glutaric aciduria type I, cause accumulation of potentially neurotoxic lysine-derived metabolites. Current therapies incompletely prevent metabolite accumulation and neurological sequelae. We evaluated whether hepatic AASS silencing could reduce conversion of lysine into downstream metabolites. Antisense oligonucleotides and small interfering RNAs targeting AASS reduced disease-associated metabolites in patient-derived cells from individuals with ALDH7A1 deficiency and glutaric aciduria type I. Hepatocyte-selective delivery, enabled by N -acetylgalactosamine conjugation, achieved >90% liver-specific Aass knockdown in wild-type and Aldh7a1 knockout mice, with sustained protein suppression and reduced accumulation of downstream lysine-derived metabolites. These findings support further evaluation of oligonucleotide-mediated AASS silencing, including liver-directed delivery, as a substrate reduction strategy for ALDH7A1 deficiency and glutaric aciduria type I.

Science Translational MedicineVol. 18(876)
University of Ottawa (CA), Duke University (US), University of Washington (US), Medical University of Graz (AT), Children's Hospital of Eastern Ontario (CA), Great Ormond Street Hospital (GB), Great Ormond Street Hospital for Children NHS Foundation Trust (GB), Institute of Child Health (IN), Duke University Hospital (US), NIHR Great Ormond Street Hospital Biomedical Research Centre (GB), University College London (GB)
UK Research and Innovation, National Institute for Health and Care Research, Royal Society, University College London, National Natural Science Foundation of China, Medical Research Council
Good health and well-being
Metabolism and Genetic Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon